ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2478 • ACR Convergence 2023

    Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases

    Janna Shapiro1, Florence Choi2, Amy Xu3, Trang Duong4, Anne-Claude Gingras5, Sasha Bernatsky6, Susanne (Susa) Benseler7 and Rae Yeung8, 1University of Toronto, Toronto, ON, Canada, 2Hong Kong Hospital Authority, Hong Kong, Hong Kong, 3Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 7University of Calgary, Calgary, AB, Canada, 8The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
  • Abstract Number: 2494 • ACR Convergence 2023

    Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis

    Salem Almaani1, Arnon Arazi2, Huijuan Song3, Pearlly Yan3, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Samir Parikh3 and Brad Rovin3, 1Ohio State University Medical Center, Columbus, OH, 2Broad Institute of MIT and Harvard, Melrose, MA, 3Ohio State University, Columbus, OH

    Background/Purpose: The role of complement in patients with ANCA-associated vasculitis (AAV) has been increasingly appreciated and led to the use of complement system antagonists as…
  • Abstract Number: 2495 • ACR Convergence 2023

    Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

    Natalie Atallah1, Vahe Panossian2, Xiaoqing Fu1, Claire Cook1 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2American University of Beirut, Beirut, Lebanon, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
  • Abstract Number: 2481 • ACR Convergence 2023

    Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

    Matthew Wright1, Mette Smed2, Lee Nelson3, Jørn Olsen4, Merete Hetland5, Nicholas Jewell6, Vibeke Zoffmann2 and Damini Jawaheer1, 1Northwestern University, Chicago, IL, 2Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, 3Fred Hutchinson Cancer Center, Seattle, WA, 4Aarhus University Hospital, Aarhus, Denmark, 5Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6London School of Hygiene and Tropical Medicine, London, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
  • Abstract Number: 2498 • ACR Convergence 2023

    Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

    Sydney Liles1, Daniel White2, Thomas Bye2 and Jason Jakiela2, 1University of Delaware, Elkton, MD, 2University of Delaware, Newark, DE

    Background/Purpose: Knee osteoarthritis (OA) is a leading global cause of pain and disability, with no current cure. Knee pain is the most common symptom and…
  • Abstract Number: 2471 • ACR Convergence 2023

    Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts

    Sabryne Berkani1, Ainhoa Aparicio Monforte2, Sophie tuffet2, alexandra rousseau2, nathalie rincheval3, emmanuel maheu4, bernard combe3, Alain SARAUX5, Bruno Fautrel6, Laure Gossec7, Francis Berenbaum4, Jeremie SELLAM6 and alice courties4, 1Sorbonne Université, Rheumatology department, (AP-HP) Saint-Antoine Hospital, Paris, France, 2Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), APHP, Hôpital St Antoine, Paris, France, 3Department of Rheumatology, University of Montpellier, Montpellier, France, 4Sorbonne Université Assistance Publique – Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Department of Rheumatology, Paris, France, 5CHU Brest, Brest, France, 6Sorbonne Université APHP, Paris, France, 7Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose: Hand osteoarthritis (HOA) is considered as a less severe disease with a better functional prognosis and a lower global burden than rheumatoid arthritis (RA).…
  • Abstract Number: 2492 • ACR Convergence 2023

    The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

    Rula Hajj-Ali1, Chao Zhang2, Renee Borchin3, Jenn Gordon4, David Cuthbertson3, Carol McAlear5, Christine Yeung5, David Badenoch6, Cristina Burroughs3 and Peter Merkel5, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3University of South Florida, Tampa, FL, 4Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA

    Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…
  • Abstract Number: 2497 • ACR Convergence 2023

    Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus

    Joy Buie, Lupus Foundation of America, York, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by its heterogeneity and cycles of flares and remissions. Owing to non-specific or incomplete…
  • Abstract Number: 2493 • ACR Convergence 2023

    Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis

    Maxime Vignac1, Dorian Nezam2, François Grolleau3, Pauline Morel4, Dimitri Titeca-Beauport5, Stanislas Faguer6, alexandre Karras7, Justine Solignac8, Noémie Jourde-Chiche9, Francois Maurier10, Hamza Sakhi1, Khalil El Karoui1, Rafik Mesbah11, Pierre Louis Carron12, Vincent Audard1, Didier Ducloux13, Romain Paule14, Jean-François Augusto15, Julien Aniort16, Aurélien Tiple16, Cédric Rafat1, Xavier Puéchal17, Pierre Gobert18, Catherine Hanrotel19, Stéphane Bally20, Nihal Martis21, Cécile-Audrey Durel22, Pascal Godmer23, Aurélie Hummel24, François Perrin25, Antoine Néel26, Claire De Moreuil27, Tiphaine Goulenok28, Dominique Guerrot29, Aurelie Foucher30, Alban DEROUX12, Loic Guillevin31, Alexis REGENT32, Raphaël Porcher3 and Benjamin Terrier33, 1APHP, Paris, France, 2CH du Havre, Havre, France, 3Université Paris Cité, Paris, France, 4AURA Paris Plaisance, Paris, France, 5CHU Amiens, Amiens, France, 6CHU Toulouse, Toulouse, France, 7HEGP - APHP, Paris, France, 8APHM, Marseille, France, 9AP-HM, Marseille, France, 10Hôpitaux privés de Metz, Vaux / Frankreich, France, 11Boulogne Hospital (CH), Boulogne, France, 12CHU de Grenoble, Grenoble, France, 13CHU de Besançon, Besançon, France, 14Hôpital Foch, Paris, France, 15CHU d'Angers, Angers, France, 16CHU de Clermont Ferrand, Clermont Ferrand, France, 17National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 18Clinique Rhône Durance, Avignon, France, 19CHU Brest, Brest, France, 20CH Métropole Savoie, Chambery, France, 21CHU de Nice, Nice, France, 22CHU Lyon, Lyon, France, 23CH Bretagne Atlantique, Vannes, France, 24CHU Necker, Paris, France, 25CH Saint Nazaire, Saint Nazaire, France, 26CHU de Nantes, Nantes, France, 27CHU de Brest, Brest, France, 28Assistance Publique Hopitaux de Paris, Paris, France, 29CHU Rouen, Rouen, France, 30CHU de la Réunion, Saint pierre, France, 31University Paris Descartes, Paris, France, 32CHU Cochin, Université Paris Cité, Paris, France, 33Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
  • Abstract Number: 2482 • ACR Convergence 2023

    Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis

    Takayuki Fujii1, Dana Orange2, Caryn Hale2, Koichi Murata1, Hideo Onizawa1, Akira Onishi1, Masao Tanaka3, Akio Morinobu4 and Shuichi Matsuda5, 1Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Rockefeller University, New York, NY, 3Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: This study aimed to determine predictors of treatment response and radiographic progression following the initiation of biological disease-modifying antirheumatic medications (bDMARDs) in patients with…
  • Abstract Number: 2474 • ACR Convergence 2023

    Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience

    Ilaria Maccora1, Valerio Accardo2, Marco Cattalini3, ilaria Pagnini4, Andrea Taddio5, Edoardo Marrani6, francesco La Torre7, Matteo Trevisan8, Maria Vincenza Mastrolia9 and Gabriele Simonini10, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2University of Florence, Florence, Italy, 3Spedali Civili di Brescia, Brescia, Italy, 4Meyer Children's Hospital IRCCS, Florence, Italy, 5Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, 6University of Florence, Firenze, Italy, 7Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, 8IRCCS Burlo Garofalo, Trieste, Italy, 9NEUROFARBA Department, University of Florence, Florence, Italy, 10Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy

    Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
  • Abstract Number: 2484 • ACR Convergence 2023

    Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management

    Ruchi Patel1, Kristen Salava1, Eric Newman2, Joseph Chronowski1, Dante Grassi1, Hillary Harris3, Amanda Young1, Idorenyin Udoeyo2, Lisa Schroeder2, David Bulbin4, David Pugliese5 and Jonida Cote6, 1Geisinger Medical Center, Danville, PA, 2Geisinger, Danville, PA, 3Geisinger, Wilkes Barre, PA, 4Geisinger Health System, Danville, PA, 5Geisinger Health System, Wilkes-Barre, PA, 6Geisinger Medical Center, Orefield, PA

    Background/Purpose: More effective teamwork can improve patient care. We studied the effect of a Rheumatologist-Pharmacist Co-management program on the quality of care of rheumatology patients…
  • Abstract Number: 2396 • ACR Convergence 2023

    Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

    Jean-Charles Mourot1, Sai Yan Yuen2, Mihaela Popescu3 and Nicolas Richard4, 1Université de Montréal, Mont-Royal, QC, Canada, 2Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, 3Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, 4Hopital Maisonneuve Rosemont, Montreal, QC, Canada

    Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
  • Abstract Number: 2391 • ACR Convergence 2023

    Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register

    Javier Narvaez1, Jesús Sanchez-Costa2, Iñigo Hernández-Rodríguez3, Rafael Benito Melero-Gonzalez4, Eugenio De Miguel5, Irene Monjo6, Maite silva díaz7, LUCIA SILVA FERNANDEZ8, Joaquin Maria Belzunegui Otano9, Jesus Alejandro Valero-Jaimes10, Clara Moriano Morales11, Ismael González12, Julio Sanchez Martin13, Tomas Almorza Hidalgo14, Judit Lluch15, Eva Galindez-Agirregoikoa16, Itziar Calvo-Zorrilla16, Vicente Aldasoro17, Javier Mendizabal18, LYDIA ABASOLO19, PIA LOIS20, Javier Loricera13, Noemi Garrido-Puñal21, ALBERTO MARIANO RUIZ ROMAN22, Santos Castañeda23, Cristina Valero23, Patricia Moya Albarado24, Hector Corominas25, Maria J. García-Villanueva26, Carmen Larena27, Paula V. Estrada-Alarcón28, Vanessa Navarro29, Carles Galisteo30, Anne Riveros-Frutos31, Francisco Miguel Ortiz Sanjuan32, Selene Labrada-Arrabal33, María Alcalde34, Clara Molina Almela35, Carlos Garcia Porrua36, Maria García-González37, Margarida Rocha38, Antonio Juan Mas39, Miguel A Gonzalez-Gay40 and Ricardo Blanco41, 1Hospital Universitario de Bellvitge, Barcelona, Spain, 2Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, 3Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 4CHU Vigo, O Carballino, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6University Hospital La Paz, Madrid, Spain, 7Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 8Complejo Hospitalario Universitario de la Coruña, Pontevedra, Spain, 9University Hospital Donostia, Donostia-San Sebasti, Spain, 10Hospital Bidasoa, Irún, Spain, 11Rheumatology, Hospital Universitario de León, León, Spain, 12Hospital Universitario de León, León, Spain, 13Hospital Universitario Marqués de Valdecilla, Santander, Spain, 14Hospital Universitario 12 de Octubre, Madrid, Spain, 15Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 16Basurto University Hospital, Bilbao, Spain, 17Hospital Universitario de Navarra, Pamplona, Spain, 18Complejo Hospitalario de Navarra, Pamplona, Spain, 19Hospital Clínico San Carlos, Madrid, Spain, 20Hospital Clinico San Carlos, Madrid, Spain, 21Hospital Universitario Virgen del Rocío, Sevilla, Spain, 22Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 23Hospital Universitario de la Princesa, Madrid, Spain, 24Hospital Universitario de Sant Pau, Barcelona, Spain, 25Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 26Hospital Ramón y Cajal, Madrid, Spain, 27Hospital Universitario Ramon y Cajal, Madrid, Spain, 28Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 29Hospital de Sant Joan Despí – Moises Broggi, Barcelona, Spain, 30Hospital Universitario Parc Taulí, Sabadell, Spain, 31Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 32Hospital Universitario y Politecnico La Fe, Valencia, Spain, 33Hospital del Mar, Barcelona, Spain, 34Hospital Severo Ochoa, Madrid, Spain, 35Hospital General de Valencia, Valencia, Spain, 36Hospital Universitario Lucus Augusti, Lugo, Spain, 37Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 38Osakidetza, Bilbo, Spain, 39Hospital Universitario Son Llàtzer, Mallorca, Spain, 40IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 41Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: The relapse rate of treated patients with giant cell arteritis (GCA) varied widely in observational series and randomized controlled trials. This study aimed to…
  • Abstract Number: 1976 • ACR Convergence 2023

    Distribution and Validity of Proposed Disability Categories from the Short-Valued Life Activities Questionnaire

    Louise Thoma1, Kelli Allen2, Beth Jonas3 and Patti Katz4, 1University of North Carolina, Chapel Hill, NC, 2University of North Carolina, Durham, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4University of California San Francisco, San Rafael, CA

    Background/Purpose: Rehabilitation (i.e., physical therapy and occupational therapy) is indicated to improve function and participation in life activities. Rehabilitation utilization is low among adults with…
  • « Previous Page
  • 1
  • …
  • 464
  • 465
  • 466
  • 467
  • 468
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology